10-Q: Agilent Q1 Revenue Up 7% to $1.79B, Net Income Dips

Agilent Technologies reports a 7% increase in Q1 net revenue to $1.798 billion, driven by growth across all segments and regions, despite a 4% decline in net income to $305 million.

Summary

• Net revenue for the three months ended January 31, 2026, increased 7% to $1,798 million compared to $1,681 million in the prior year period.
• Foreign currency movements had a 3 percentage point favorable impact on revenue growth.
• Net income decreased 4% to $305 million, down from $318 million in the prior year.
• Diluted net income per share was $1.07, a decrease from $1.11 in the prior year.
• Cash provided by operating activities was $268 million, a significant decrease from $431 million in the same period last year.
• Total gross margin decreased by 1 percentage point to 52.6%, and operating margin decreased by 3 percentage points to 19.7%.
• The company repurchased 1.050 million shares for $152 million under the 2024 repurchase program, with approximately $1,797 million remaining authorization.
• Restructuring and other related costs for the quarter amounted to $20 million.
• A quarterly dividend of $0.255 per common share ($72 million) was paid and another declared for April 22, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While revenue growth is strong and broad-based, the decline in net income, operating margin, and cash from operations, coupled with increased tax expenses and DSO, indicates profitability and efficiency challenges that temper the positive top-line performance.

Positives

• Total net revenue increased 7% year-over-year to $1,798 million, demonstrating strong top-line growth.
• Revenue growth was broad-based, with increases across all segments (Life Sciences and Diagnostics Markets, Agilent CrossLab, Applied Markets) and all geographic regions.
• The Agilent CrossLab segment showed robust performance with a 9% revenue increase, driven by strength in repair, maintenance, compliance services, consumables, and software.
• The Applied Markets segment grew 7%, primarily due to strong revenue growth in the chemicals and advanced materials markets.
• The Life Sciences and Diagnostics Markets segment increased 5%, with strong growth in the pharmaceutical and diagnostics and clinical markets.
• Foreign currency movements contributed a favorable 3 percentage point impact to overall revenue growth.
• The company expects to fully offset the adverse impact of tariff changes on costs of revenue during fiscal year 2026 through mitigation strategies.
• Maintained strong liquidity with $1,758 million in cash and cash equivalents as of January 31, 2026.
• Continued commitment to shareholder returns through a significant share repurchase program and consistent quarterly dividends.

Negatives

• Net income decreased 4% to $305 million, down from $318 million in the prior year, despite higher revenue.
• Diluted net income per share declined to $1.07 from $1.11.
• Cash provided by operating activities significantly decreased to $268 million from $431 million in the prior year, a 38% reduction.
• Total gross margin decreased by 1 percentage point to 52.6%, impacted by higher tariffs, unfavorable business mix (lower gross margin from specialty CDMO), wage increases, higher variable pay, and restructuring costs.
• Operating margin decreased by 3 percentage points to 19.7%, primarily due to higher tariffs, corporate infrastructure expenses, restructuring costs, and transformational initiative expenses.
• Income from operations decreased 6% to $353 million despite a 7% increase in revenue.
• Income tax expense increased to $59 million (16.2% effective rate) from $49 million (13.4% effective rate), partly due to Pillar Two rules and the OBBBA.
• Cash paid for income taxes significantly increased to $105 million from $19 million in the prior year.
• Days sales outstanding (DSO) increased to 76 days as of January 31, 2026, from 71 days as of January 31, 2025.

Risks

• General economic conditions, including slower global growth, increasing interest rates, and inflationary pressures, may adversely affect operating results and financial condition by reducing demand, increasing order cancellations, and intensifying price pressure.
• Fluctuations in foreign currency exchange rates and geopolitical instability (e.g., conflicts in Ukraine/Russia and the Middle East, trade uncertainties in Greater China) could negatively impact international sales and operations, increasing costs and affecting profitability.
• Ongoing and future tariffs, particularly those imposed by the U.S. government on goods from other countries, could have a material adverse effect on business, results of operations, and financial condition.
• Failure to introduce successful new products and services in a timely manner, amidst rapid technological changes and intense competition, could lead to product obsolescence and harm operating results.
• Demand for products and services is highly dependent on customer capital spending policies, research and development budgets, and government funding, which are subject to unpredictable fluctuations.
• Recent and dynamic government rulemaking and policy changes, including new regulations, tariffs, sanctions, and export controls, could increase costs, disrupt supply chains, and require operational adjustments.
• Inability to adjust purchases to changing market conditions or accurately estimate customer demand could lead to excess and obsolete inventories and increased expenses.
• Failure to retain and hire key personnel, especially in highly technical specialties, could hinder business expansion and innovation.
• Strategic initiatives to adjust cost structure, such as restructuring programs, may distract management, slow product improvements, and not yield anticipated operational or financial benefits.
• Acquisitions, strategic investments, and divestitures may result in unexpected financial results, integration difficulties, significant costs, and potential impairment charges.
• Public health crises (epidemics and pandemics) pose risks to global operations, supply chains, sales, and delivery of products and services, with uncertain duration and severity.
• Failure to maintain an effective system of internal controls could lead to inaccurate financial reporting and a loss of investor confidence.
• Non-compliance with extensive governmental regulations (e.g., FDA, environmental, data privacy, anti-bribery) could result in significant expenses, product recalls, civil/criminal penalties, and reputational harm.
• Issues in the development, deployment, and use of artificial intelligence (AI) technologies, including inaccurate algorithms, data leakage, ethical concerns, and security risks, may result in reputational harm, regulatory action, or legal liability.
• Third parties may claim intellectual property infringement, leading to costly litigation, licensing expenses, product redesigns, or injunctions against product sales.
• Operating results may suffer if manufacturing capacity does not match product demand, leading to either excess capacity costs or an inability to fulfill orders.
• Dependence on contract manufacturing and outsourcing of supply chain, IT, and administrative functions may adversely affect the ability to bring products to market, damage reputation, or impair effective operation.
• Catastrophic losses to factories, facilities, or distribution systems due to natural disasters, terrorism, or extreme weather events could seriously harm operations and lead to large expenses.
• Retirement and post-retirement pension plans are subject to financial market risks (e.g., interest rates, asset performance) that could adversely affect future results of operations and cash flows.
• Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on results of operations, financial condition, and liquidity.
• Outstanding debt and potential future debt incurrence could adversely affect financial condition and liquidity by increasing vulnerability to downturns and dedicating cash flow to debt service.
• The timing, declaration, amount, and payment of any future dividends are subject to the discretion of the Board of Directors and are not assured.

Future Outlook

Agilent expects to fully offset the adverse impact of tariff changes on costs of revenue during fiscal year 2026 through mitigation strategies including supply chain optimization, targeted pricing actions, and cost-efficiency initiatives. The company remains optimistic about the long-term health of its key end markets and anticipates continued steady market recovery, particularly in applied markets. Primary focus areas include enhancing customer experience, delivering differentiated product solutions, driving productivity improvements, and continued investment in research and development, application and solutions portfolios, and expansion in developing and emerging markets. Capital expenditures for the current year are projected to be approximately $500 million, largely for expanding nucleic acid-based therapeutics manufacturing capacity in Frederick, Colorado.

Management Comments

• "Our primary focus remains on enhancing our customers experience, delivering differentiated product solutions and driving productivity improvements."
• "After an extended period of constrained capital spending, many customers' ability to spend capital budgets has begun to normalize, with the exception of customers receiving funding from the U.S. federal government."
• "We remain optimistic about the long-term health of our key end markets."
• "While the tariff changes adversely impacted our costs of revenue during the three months ended January 31, 2026, we expect to fully offset the current impact during our fiscal year 2026."
• "Although the tariff situation is still evolving, we expect to pursue mitigation strategies through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins and sustain long-term growth."
• "The rising demand for several of the modalities provided by our specialty CDMO business positions us well to serve expanding customer demand."
• "By leveraging our liquid chromatography and liquid chromatography mass spectrometry platforms, we are driving growth across key markets and remain optimistic about long-term life sciences opportunities."
• "Agilent CrossLab is well positioned to continue its success in our key end markets by supporting a growing installed base of instruments."
• "Digital and remote capabilities will continue to be a key factor in improving the service quality and the customers' experience."
• "We also anticipate continued steady market recovery and are optimistic about our long-term growth opportunities in the applied markets as our broad portfolio of products and solutions are well suited to address customer needs."

Industry Context

StockSavvy.ai notes that Agilent's performance reflects a mixed but generally positive trend in the life sciences, diagnostics, and applied markets, with strong revenue growth across segments indicating robust demand for laboratory solutions. The company's emphasis on enhancing customer experience, differentiated product solutions, and productivity improvements aligns with broader industry trends focusing on value-added services and operational efficiency. The normalization of customer capital spending, excluding U.S. federal government funding, suggests a gradual recovery in market conditions, while ongoing geopolitical and trade uncertainties, particularly regarding tariffs, remain a sector-wide concern requiring adaptive supply chain and pricing strategies. The increasing demand for specialty CDMO services and the growth of diagnostic and clinical markets highlight key areas of expansion within the broader healthcare and research sectors.

Comparison to Industry Standards

• Agilent's 7% revenue growth is competitive within the analytical instrument and life sciences tools sector, which often sees mid-to-high single-digit growth. Companies like Thermo Fisher Scientific and Danaher Corporation, while larger, typically target similar growth profiles, often augmented by M&A.
• The decline in gross and operating margins due to tariffs and business mix is a common challenge for global manufacturers, particularly those with significant exposure to regions impacted by trade policies. Peers might also face similar pressures, but the extent of the 1-3 percentage point drop warrants attention.
• The increase in Days Sales Outstanding (DSO) to 76 days from 71 days is a slight deterioration in working capital efficiency. Leading companies in the sector typically aim for DSOs in the 60-70 day range, suggesting Agilent is slightly above optimal, which could impact cash conversion cycle compared to best-in-class operations.
• The planned $500 million capital expenditure for manufacturing expansion, particularly for nucleic acid-based therapeutics in Frederick, Colorado, aligns with strategic investments seen across the industry. Major players like Lonza and Catalent (CDMOs) or even instrument providers like Sartorius are also heavily investing in bioprocessing and advanced therapy manufacturing to meet growing demand.
• The ongoing share repurchase program and consistent dividend payments are standard practices for mature, cash-generative companies in the sector, reflecting a commitment to shareholder returns, comparable to policies at companies like Waters Corporation or PerkinElmer.

Legal Proceedings

• Involved in lawsuits, claims, investigations, and proceedings, including intellectual property, commercial, real estate, environmental, and employment matters, arising in the ordinary course of business.
• No matters pending are currently believed to be probable and reasonably possible of having a material impact to the business, consolidated financial condition, results of operations, or cash flows.

Related Party Transactions

• Received $3 million in income from the provision of site service costs to, and lease income from, Keysight Technologies, Inc. for both the three months ended January 31, 2026, and 2025.

Stakeholder Impact

• Shareholders are impacted by decreased net income and diluted EPS, but benefit from continued share repurchases ($152 million in Q1) and consistent quarterly dividends ($0.255 per share declared).
• Employees are affected by the ongoing FY25 restructuring plan (workforce reduction) but also benefit from wage increases and higher variable pay; overall headcount slightly increased.
• Customers will benefit from the company's focus on enhancing customer experience, delivering differentiated product solutions, and continued investment in R&D and application portfolios, with potential for improved service quality through digital and remote capabilities.
• Suppliers and creditors may experience impacts from tariff changes and supply chain optimization efforts; the company maintains stable access to short-term financing through credit facilities and commercial paper programs.
• Regulatory bodies continue to oversee the company's compliance with various regulations (SEC, FDA, environmental, data privacy, anti-bribery) and monitor its responses to evolving trade dynamics and tax law changes (Pillar Two, OBBBA).

Next Steps

• Monitor evolving trade dynamics and potential future U.S. governmental responses to tariffs.
• Pursue mitigation strategies for tariffs through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins.
• Continue enhancing customer experience, delivering differentiated product solutions, and driving productivity improvements.
• Continue investing in research and development, advancing application and solutions portfolios, and expanding position in developing and emerging markets.
• Substantially complete FY25 restructuring activities by the end of fiscal year 2026.
• Contribute approximately $15 million to defined benefit plans during the remainder of 2026.
• Complete planned expansion of manufacturing capacity for nucleic acid-based therapeutics in Frederick, Colorado.
• The Board of Directors will determine and approve the timing and amounts of any future dividends.
• Tax audits may be completed over the next twelve months in the U.S. and other major jurisdictions.

Key Dates

Recommendation

While Agilent demonstrated solid revenue growth across all segments and regions, indicating strong market demand for its products and services, the decline in net income, operating margin, and cash flow from operations is a concern. These profitability pressures stem from higher tariffs, unfavorable business mix, wage increases, and restructuring costs. The company's proactive mitigation strategies for tariffs and continued investments in R&D and manufacturing capacity are positive long-term indicators. However, the immediate impact on earnings and cash generation suggests a period of adjustment. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of cost-efficiency initiatives and the trajectory of profitability in subsequent quarters before making a more definitive move.

Keywords

Life Sciences, Diagnostics, Applied Markets, Analytical Instruments, Laboratory Workflow, Pharmaceutical, Biotechnology, CDMO, Pathology, Genomics, Liquid Chromatography, Mass Spectrometry, Consumables, Services, Software, Share Repurchase, Dividends, SEC 10-Q, Financial Results, Tariffs, Restructuring, Corporate Governance, Risk Management, Artificial Intelligence